Publications by authors named "Bernd A Kamppeter"
Background/aims: Proliferative retinopathies remain the most common causes of blindness. Retinal neovascularisation is induced by hypoxic upregulation of angiogenic growth factors, such as vascular endothelial growth factor (VEGF). Thalidomide has been shown to be anti-angiogenic via reduction of VEGF levels.
View Article and Find Full Text PDFPurpose: To examine the decrease in the intraocular concentration of intravitreally injected triamcinolone acetonide over an 8-month period in a rabbit model.
Design: Experimental study.
Participants: The study included 18 white New Zealand rabbits.
Objective: The aim of this study was to compare the visual acuity change after an intravitreal high-dose injection of triamcinolone acetonide (TA) in various types of exudative age-related macular degeneration (AMD).
Participants: The interventional comparative case series study included 142 patients (146 eyes) with progressive exudative AMD differentiated into the occult type (n = 78; 53.4%), minimal classic type (n = 45; 30.
Background: Intravitreal triamcinolone acetonide has been discussed as treatment for exudative age-related macular degeneration (AMD).
Objectives: To give an updated report on repeated intravitreal injections of triamcinolone acetonide (IVTA) for the treatment of exudative AMD.
Methods: The case-series study included 24 patients (24 eyes) with progressive exudative AMD who had shown an increase in, or stabilization of, visual acuity after a first IVTA, and who eventually experienced a deterioration of visual acuity.
Purpose: To examine the tolerance and mechanical function of an adjustable intraocular lens (IOL) in rabbit eyes.
Methods: Implantation of the *Acri.Tec AR-1 PC/IOL into 14 rabbit eyes.
Purpose: The aim of this study is to report on the clinical course of a patient showing markedly increased intraocular pressure (IOP) caused by intravitreal triamcinolone acetonide.
Methods: A 33-year-old patient received an intravitreal injection of approximately 20 mg of triamcinolone acetonide (TA) as treatment of otherwise therapy-resistant uveitis. She experienced an IOP rise to values over 40 mmHg for a period for more than 3 months, despite maximal antiglaucomatous medical therapy.
Purpose: The aim of this study was to examine the visual outcome of patients receiving an intravitreal injection of triamcinolone acetonide (TA) as treatment of diffuse diabetic macular edema (DDME).
Methods: This prospective, placebo-controlled, randomized, clinical interventional study included 40 eyes (38 patients) with DDME, with 28 (70%) eyes randomized to treatment and 12 (30%) eyes randomized to receive a placebo injection. Thirty-six (36) (90%) eyes completed the 3-month study visit, and 32 (80%) eyes completed the 6-month study visit.
Objective: The aim of this study was to evaluate the duration of the effect of an intravitreal injection of approximately 20 mg of triamcinolone acetonide (TA) on visual acuity and intraocular pressure (IOP) in patients with exudative age-related macular degeneration (AMD) with subfoveal choroidal neovascularization.
Participants: The prospective, clinical, interventional, case series study included 69 patients (71 eyes) with exudative AMD who showed an increase in visual acuity by at least 2 Snellen lines after an intravitreal injection of approximately 20 mg TA. Mean follow-up was 11.
Purpose: Optical coherence tomography may be a new technique for quantitative 3-dimensional assessment of the optic nerve head for diagnosis of optic nerve anomalies and diseases such as the glaucomas. The purpose of the present study was to examine its reproducibility.
Patients And Methods: The clinical noninterventional study included 10 randomly chosen eyes of 10 healthy individuals who underwent 24 optical coherence tomographic examinations with the high-resolution and fast scan program, interactively corrected or uncorrected.
Objective: To report the results of repeated intravitreal injections of triamcinolone acetonide for treatment of diffuse diabetic macular edema.
Design: Retrospective interventional comparative study.
Participants: The investigation included a study group (the responders) of 19 patients (22 eyes) with diffuse diabetic macular edema, who showed an improvement in visual acuity after an intravitreal injection of approximately 20 mg triamcinolone acetonide, and who received a second intravitreal injection 10.
Purpose: To compare dynamic contour tonometry as a new method for intraocular pressure measurement with Goldmann applanation tonometry.
Design: Clinical observational study.
Methods: The study included 176 eyes of 126 subjects (39 eyes with open-angle glaucoma, 137 normal eyes) and consisted of 528 dynamic contour measurements and 352 Goldmann tonometry measurements.
Purpose: To report on visual outcome after intravitreal injection of triamcinolone acetonide for exudative age-related macular degeneration.
Design: Interventional comparative non-randomized clinical trial.
Setting: Institutional.
Purpose: To report on intraocular pressure (IOP) after intravitreal injections of triamcinolone acetonide.
Design: Meta-analysis of previously reported data and case series studies.
Participants: The study included 272 patients (305 eyes) receiving an intravitreal injection of approximately 20 mg triamcinolone acetonide as treatment for diffuse diabetic macular edema (n = 84 patients), exudative age-related macular degeneration (n = 181 patients), retinal vein occlusions (n = 20 patients), uveitis (n = 9), pseudophakic cystoid macular edema (n = 6), and other reasons (n = 5).
Purpose: To report on visual outcome of patients receiving intravitreal triamcinolone acetonide for treatment of diffuse diabetic macular edema.
Design: Prospective, comparative clinical interventional study.
Setting: Institutional.
Purpose: To evaluate the duration of the effect of intravitreal triamcinolone acetonide on visual acuity in patients with diffuse diabetic macular edema.
Design: Clinical interventional case series.
Methods: Subjects were 31 patients (38 eyes) with diffuse diabetic macular edema who received an intravitreal injection of 20- to 25-mg triamcinolone acetonide.
Purpose: To evaluate whether it is technically feasible and safe to implant and adjust an intraocular lens (IOL) with reversibly adjustable refractive power designed to correct residual postoperative refractive error.
Setting: Animal study facility, Klinikum Mannheim, University of Heidelberg, Heidelberg, Germany.
Methods: An Acri.